ProShares UltraPro S&P 500 Sees Significant Influx of Capital

Written by Emily J. Thompson, Senior Investment Analyst

TMO+0.5%

TSLA+4.15%

PLTR+0.34%

Source: NASDAQ.COM

Updated: Dec 03 2025

0mins

Source: NASDAQ.COM

52-Week Range of UPRO: UPRO's share price has a 52-week low of $45.88 and a high of $122.19, with the last trade recorded at $116.31.
Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), impacting the underlying assets.
Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

TMO

$639.45+Infinity%1D

Analyst Views on TMO

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

19 Analyst Rating

18 Buy

1 Hold

0 Sell

Strong Buy

Current: 636.300

Low

580.00

Averages

658.89

High

750.00

Current: 636.300

Low

580.00

Averages

658.89

High

750.00

Stifel

Daniel Arias

Buy

maintain

$583 -> $700

2026-01-09

Reason

Stifel

Daniel Arias

Price Target

$583 -> $700

AI Analysis

2026-01-09

maintain

Buy

Reason

Stifel analyst Daniel Arias raised the firm's price target on Thermo Fisher to $700 from $583 and keeps a Buy rating on the shares. Considering the outlook for 2026, the firm believes Thermo is set up to have a solid year that pushes organic growth back into the mid-single-digits and EPS growth into the high-single-digits, the analyst tells investors.

TD Cowen

Buy

maintain

$654 -> $696

2026-01-07

Reason

TD Cowen

Price Target

$654 -> $696

2026-01-07

maintain

Buy

Reason

TD Cowen raised the firm's price target on Thermo Fisher to $696 from $654 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TMO

Unlock Now

Evercore ISI

Vijay Kumar

Outperform

maintain

$610 -> $650

2026-01-05

Reason

Evercore ISI

Vijay Kumar

Price Target

$610 -> $650

2026-01-05

maintain

Outperform

Reason

Evercore ISI analyst Vijay Kumar raised the firm's price target on Thermo Fisher to $650 from $610 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

BofA

Buy

maintain

$650 -> $700

2025-12-15

Reason

BofA

Price Target

$650 -> $700

2025-12-15

maintain

Buy

Reason

BofA raised the firm's price target on Thermo Fisher to $700 from $650 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

About TMO

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.